The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 14, 2025

Filed:

Sep. 19, 2022
Applicants:

Amgen Inc., Thousand Oaks, CA (US);

Amgen Research (Munich) Gmbh, Munich, DE;

Inventors:

Shouhua Xiao, Foster City, CA (US);

Zheng Pan, Fremont, CA (US);

Dineli Wickramasinghe, San Francisco, CA (US);

M. Shawn Jeffries, Indianapolis, IN (US);

Chadwick Terence King, North Vancouver, CA;

Brian Mingtung Chan, Port Coquitlam, CA;

Peter Kufer, Munich, DE;

Ralf Lutterbüse, Munich, DE;

Tobias Raum, Munich, DE;

Patrick Hoffmann, Munich, DE;

Doris Rau, Munich, DE;

Roman Kischel, Munich, DE;

Bryan Lemon, Mountain View, CA (US);

Holger Wesche, San Francisco, CA (US);

Assignees:

AMGEN INC., Thousand Oaks, CA (US);

AMGEN RESEARCH (MUNICH) GMBH, Munich, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 47/60 (2017.01); C07K 16/30 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2809 (2013.01); A61K 47/60 (2017.08); C07K 16/28 (2013.01); C07K 16/2896 (2013.01); C07K 16/3053 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01); C07K 2317/73 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01);
Abstract

Provided are antibody constructs comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Also provided are nucleic acids encoding the antibody constructs, vectors comprising the nucleic acids, and host cells transformed or transfected with the vectors. Further provided are a process for the production of the antibody constructs, methods of using the antibody constructs and a kit comprising the antibody constructs.


Find Patent Forward Citations

Loading…